Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Summary
Phase 1b consists of combined dose escalation phase and dose expansion phase. Phase 3 study will compare efficacy and safety of IBI351 combined with cetuximab versus chemotherapy in treatment of KRAS G12C-mutated metastatic colorectal cancer
Official title: An Open-label, Multicenter, Phase Ib/III Study of Efficacy and Safety of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2022-08-18
Completion Date
2025-01-24
Last Updated
2026-08-19
Healthy Volunteers
No
Conditions
Interventions
IBI351
IBI351 is administered orally
Cetuximab
Cetuximab is administered intravenously
Locations (1)
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China